Wie hoch ist der Preis für Algernon Pharmaceuticals Inc. (AGN)

Preis für Algernon Pharmaceuticals Inc. (AGN) ist $0.29357476

Wie hoch ist die Marktkapitalisierung für Algernon Pharmaceuticals Inc. (AGN)

Marktkapitalisierung für Algernon Pharmaceuticals Inc. (AGN) ist $1.02M

Algernon Pharmaceuticals Inc. (AGN) KUV

Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Jahr	P/S-Verhältnis	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

P/S-Verhältnis

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	P/S-Verhältnis	P/S-Verhältnis-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	9.88	-	US
Argenx SE ARGX.US	10.30	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.98	-	BE

Unternehmen

P/S-Verhältnis

P/S-Verhältnis-Differenz

Land